Lobby advocates for venture capitalists, startups
This article was originally published in The Tan Sheet
Executive SummaryFrustrated by the lack of attention innovators and startups received during the health care reform debate, the National Venture Capital Association forms a group to speak up for the groups in national affairs. NVCA announced Sept. 7 its Medical Innovation and Competitiveness will push for more recognition for startups developing devices and therapeutics and the investors that back them. Kelly Slone, director of the NVCA's medical industry group, said, "No one is paying attention to these little companies and they're the ones really driving innovation." The coalition will push for a presidentially appointed position to assess the impact of new federal policies on medical innovation. With medical and biopharma startups already squeezed in capital markets, new uncertainties emerge from health care reform and a lack of predictability in the regulatory and reimbursement realms
You may also be interested in...
As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 10)
A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this tenth and final installment of a 10-part series, the experts explain why it’s important to be honest with investigators at all times.